U.S. Drug Pricing Policy Shifts: Strategic Implications for Pharma Leaders

U.S. administration's aggressive pharmaceutical pricing offensive is reshaping the entire industry landscape. Our latest whitepaper reveals how the Most-Favored-Nation (MFN) policy and the unprecedented tariff threats could wipe out 50-60% of Big Pharma's US profits. Major pharmaceutical giants, including AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Inc., Genentech, Gilead Sciences, GSK, Johnson & Johnson, MSD, Novartis, and others, are now facing what industry analysts call "the most aggressive pharmaceutical pricing intervention in US history". With blockbuster drugs potentially facing price cuts of up to 95% and the September 29, 2025 deadline fast approaching, pharmaceutical companies are scrambling to adapt with defensive strategies ranging from voluntary price cuts to reconsidering go-to-market strategies. As we approach this critical inflection point, one question remains: Will this pricing revolution achieve patient affordability goals, or trigger the industry disruption that could undermine pharmaceutical innovation globally?